Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for autoimmune diseases. The company's lead program, CM313, is an IgG1 monoclonal antibody targeting CD38 to modulate immune cell activity. This asset is being advanced across multiple indications, including Immune Thrombocytopenia and Systemic Lupus Erythematosus, addressing significant unmet medical needs.
Funding
$180M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCFounders
Product
Problem
Current treatment options for autoimmune diseases often fail to provide rapid and durable responses, leaving a significant unmet need for patients suffering from these conditions. Existing therapies may not effectively modulate multiple arms of the immune system, leading to suboptimal outcomes.
Solution
Timberlyne Therapeutics is developing CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity (CDC) that targets CD38. CD38 is highly expressed on plasma cells, NK cells, and other immune cells, making it a compelling target for modulating the immune system. CM313 aims to provide both rapid and durable responses across a range of autoimmune diseases by targeting CD38 and leveraging its enhanced CDC activity. The antibody has undergone testing in disease states including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma.
Target Audience
The primary target audience includes patients with autoimmune diseases, as well as the physicians and healthcare providers who treat these conditions.
Features
- IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity (CDC)
- Targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells
- Designed to modulate multiple arms of the immune system
- Demonstrated activity in Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma in prior studies